All Translational Science articles
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
NewsISSCR consortium submits recommendations on NAMs to FDA
The ISSCR Consortium on Advanced Stem Cell-Based Models is calling for greater flexibilty from the FDA to accomodate rapidly changing technologies like stem cell-derived systems, organoids and computational approaches.
-
NewsC-Path launches coalition to advance human-relevant drug discovery
The New Approach Methodologies Developer Coalition brings together technology developers, pharmaceutical companies and regulators in a precompetitive initiative to establish qualification standards for complex in vitro models, microphysiological systems and related human-relevant technologies.
-
ArticleAACR 2026 part 1: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.
-
NewsMYC protein found to repair DNA in cancer cells
Oregon Health & Science University researchers have identified a non-canonical function of the MYC oncoprotein in DNA damage repair, revealing how tumour cells survive chemotherapy-induced stress.
-
NewsCD4+ T cells identified as key to hepatitis B clearance
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that explains why some chronic hepatitis B patients successfully clear the virus after stopping antiviral treatment.
-
ArticleTurning CRISPR hits into confident drug discovery decisions
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.
-
NewsRepurposed cancer drugs target root cause of Crohn’s Disease
Researchers at the University of Houston have identified epithelial stress signalling as a key driver of Crohn’s disease and demonstrated that two FDA-approved cancer drugs can interrupt the pathological cycle of cell death and inflammation.
-
ArticleWhy lower organisms matter for neurodegeneration drug discovery
In the wake of recent government policy aimed at actively replacing animal models in drug discovery, we consider a possible solution to the translational shortfalls of current cellular methodologies for neurodegenerative disease.
-
NewsNew method streamlines C–N bond formation for amine synthesis
Researchers at the University of Wisconsin–Madison have reported a new approach to forming carbon–nitrogen bonds, a critical step in the synthesis of amines widely used in pharmaceuticals, agrochemicals and polymers.
-
NewsOvarian follicles provide new platform for angiogenesis research
A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis modelling within 24 hours, offering improved drug screening capabilities that distinguish therapeutic effects from general toxicity.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsChampions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
-
NewsMassey Cancer Center funds drug discovery projects targeting Hsp27-CerS1 and ferroptosis pathways
The VCU Massey Comprehensive Cancer Center has awarded $50,000 each to two innovative drug discovery projects through its collaborative programme with Sanford Burnham Prebys Medical Discovery Institute.
-
NewsNew osteoarthritis therapy targeting joint repair advances following preclinical success
A Duke Health-led consortium has achieved key preclinical milestones in developing regenerative therapies that target cartilage and bone damage in osteoarthritis, potentially offering an alternative to symptom management and joint replacement surgery.
-
NewsFGF21 hormone targets hindbrain pathways to reverse obesity
New research reveals that FGF21, a hormone under investigation for obesity and metabolic dysfunction-associated steatohepatitis (MASH), works by signalling to the hindbrain rather than the hypothalamus. The discovery of this distinct neural circuit—which increases metabolic rate rather than simply suppressing appetite—could enable development of more precise therapies with fewer adverse effects than current FGF21 analogues.
-
ArticleFrom fragments to maps: scaling drug–target interaction data
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
NewsScientists scale up neural organoid studies for drug testing
Researchers at King’s College London have developed a hybrid neural organoid approach that addresses longstanding limitations in scalability, reproducibility and longitudinal analysis. By dissociating 3D organoids and culturing pooled cells on microelectrode arrays, the team created 2D networks that retain cellular diversity whilst enabling consistent, long-term tracking of neural activity across parallel cultures.
-
NewsImplantable ‘living pharmacy’ device produces multiple drugs inside the body
Scientists have developed an implantable device that acts as a ‘living pharmacy’, using engineered cells to continuously produce multiple therapeutic biologics inside the body. The wireless system, which generates its own oxygen supply, maintained stable drug levels for 30 days in preclinical studies.